FMP
Savara Inc.
SVRA
NASDAQ
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
2.86 USD
-0.36 (-12.59%)
Historical Prices
From:
To:
About
ceo
Mr. Matthew Pauls J.D., M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.savarapharma.comexchange
NASDAQ
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
CIK
0001160308
ISIN
US8051111016
CUSIP
805111101
Address
Building III
Phone
512 614 1848
Country
US
Employee
59
IPO Date
Apr 28, 2017
Financial Statement
Earnings
SVRA Financial Summary
CIK
0001160308
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
805111101
ISIN
US8051111016
Country
US
Price
2.86
Beta
0.44
Volume Avg.
952.74k
Market Cap
494.06M
Shares
-
52-Week
2.255-5.11
DCF
-0.06
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-5.96
P/B
-
Website
https://www.savarapharma.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SVRA News
Benzinga
Jun 26, 2024
Why Is Respiratory Disease-Focused Savara Stock Trading High...
The latest trial study from Savara Inc SVRA met its primary endpoint.
Reuters
Jun 26, 2024
Savara's rare lung disease drug meets main goal in late-stag...
Savara on Wednesday said its experimental drug, molgradex, met the main goal of a late-stage trial for treating a rare lung disease characterized by a feeling of breathlessness.
InvestorPlace
Jun 11, 2024
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: ...
Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable.
Business Wire
May 29, 2024
Savara to Present at the Jefferies Global Healthcare Confere...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:00am PT/10:00am ET. A live webcast of the fireside chat will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clin.
Business Wire
Apr 8, 2024
Savara to Present New Data on Autoimmune Pulmonary Alveolar ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA. “We look forward to seeing data presented at ATS on the significant healthcare burden facing aPAP patients, challenges for diagnosis, and the development.
Finbold
Feb 1, 2024
3 stocks to turn $100 into $1,000 in 2024
The previous year was prosperous for many investors, resulting in significant gains in the stock market. The outlook for 2024 seems promising, especially in the technology sector.
Business Wire
Jan 31, 2024
Savara to Present at Two Upcoming Healthcare Conferences
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences: Guggenheim 6th Annual Biotechnology Conference February 7, 2024 at 8:30am PT/ 11:30am ET Fireside Chat St. Regis Hotel, New York City, NY Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 at 7:40am PT / 10:40am ET Co.
InvestorPlace
Sep 27, 2023
3 Penny Stocks to Provide 1,000% Returns Over the Next Decad...
While penny stocks promise substantial potential gains, the reality is that sub-$5 stocks are among the riskiest investments. Their low price often reflects underlying issues like weak business models, high debt, dwindling market share, and uncertain prospects.
